Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $17.33 Average PT from Brokerages

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) has earned a consensus recommendation of “Buy” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $17.33.

Several research firms have recently commented on TNYA. Leerink Partners reiterated an “outperform” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a report on Wednesday. Canaccord Genuity Group restated a “buy” rating and set a $16.00 price target on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital reiterated a “buy” rating and issued a $18.00 price objective on shares of Tenaya Therapeutics in a report on Wednesday. Finally, Piper Sandler reissued an “overweight” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th.

Tenaya Therapeutics Trading Up 18.4 %

TNYA opened at $1.67 on Thursday. Tenaya Therapeutics has a twelve month low of $0.99 and a twelve month high of $7.01. The firm has a market capitalization of $132.30 million, a PE ratio of -1.16 and a beta of 2.72. The firm’s 50-day moving average price is $2.43 and its 200 day moving average price is $2.69.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. As a group, analysts predict that Tenaya Therapeutics will post -1.35 earnings per share for the current fiscal year.

Institutional Trading of Tenaya Therapeutics

Several institutional investors have recently added to or reduced their stakes in TNYA. Synovus Financial Corp purchased a new position in shares of Tenaya Therapeutics during the third quarter worth $28,000. Geode Capital Management LLC boosted its holdings in Tenaya Therapeutics by 5.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,296,156 shares of the company’s stock valued at $2,502,000 after acquiring an additional 66,968 shares during the period. XTX Topco Ltd boosted its holdings in Tenaya Therapeutics by 51.2% during the 3rd quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock valued at $95,000 after acquiring an additional 16,687 shares during the period. Wellington Management Group LLP grew its position in Tenaya Therapeutics by 35.6% in the 3rd quarter. Wellington Management Group LLP now owns 294,133 shares of the company’s stock valued at $568,000 after acquiring an additional 77,235 shares in the last quarter. Finally, State Street Corp increased its stake in Tenaya Therapeutics by 0.9% during the third quarter. State Street Corp now owns 1,058,898 shares of the company’s stock worth $2,044,000 after purchasing an additional 9,506 shares during the period. Institutional investors and hedge funds own 90.54% of the company’s stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.